Related Experiment Video
Updated: Feb 19, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Somatic Mutations and Splicing Variants of Focal Adhesion Kinase in Non-Small Cell Lung Cancer
Bo Zhou1, Gui-Zhen Wang1, Zhe-Sheng Wen2
1State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences and University of Chinese Academy of Sciences, Beijing, China.
Background:
Overexpression of focal adhesion kinase (FAK) has been reported in lung cancer, but the somatic mutations and alternative splicing variants of this nonreceptor tyrosine kinase remain to be investigated.
Methods:
FAK in 91 lung cancer patients was sequenced using genomic DNA and cDNA samples of tumor and paired normal lung tissues as templates, and the RNA-seq data of The Cancer Genome Atlas (TCGA) data set were assessed. The biological functions of abnormal FAK transcripts and their response to FAK inhibitors were analyzed in eight cell lines using tyrosine kinase activity assay, trypan blue exclusion assay, MTT (3-(4, 5)-dimethylthiahiazo (-z-y1)-3, 5-di-phenytetrazoliumromide) assay, and transwell assay.
Results:
We identified an internal tandem duplication (ITD), an A1004S point mutation, an exon 5-27 deletion (ΔE5-27) truncation variant, and four FAK6,7 splicing variants (containing exons for Boxes 6 and 7) in seven (7.7%) patients. Smokers had more FAK abnormalities than nonsmokers. In FAK-ITD, the sequence encoding the C-terminal of the FERM domain and kinase domain was duplicated in-frame and produced a protein product with elevated autophosphorylation and sensitivity to FAK inhibitors. FAK6,7 was detected in the tumor but not counterpart normal lung tissues of four (4.4%) patients. In TCGA RNA-seq data, Box 6 and/or Box 7 (Box 6/7)-containing FAK variants were positive in 42 (8.3%) of 508 lung adenocarcinomas (LUADs) and 37 (7.4%) of 501 lung squamous cell carcinomas, and smokers had higher expression of Box 6/7 (+) FAK than reformed or nonsmokers with LUAD. FAK6,7 promoted cell proliferation and migration, exhibited increased autophosphorylation, and was more sensitive to FAK inhibitor compared with wild-type FAK.
Conclusions:
Somatic mutations and splicing variants of FAK may have a role in lung carcinogenesis and represent potential biomarkers for FAK-targeted therapies.
Insights
Focal adhesion kinase (FAK) mutations and splicing variants are found in lung cancer, particularly in smokers. These FAK alterations enhance kinase activity and sensitivity to inhibitors, suggesting potential therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Focal adhesion kinase (FAK) overexpression is noted in lung cancer.
- Somatic mutations and alternative splicing of FAK are not well-understood in lung cancer.
Purpose of the Study:
- Investigate somatic mutations and alternative splicing variants of FAK in lung cancer.
- Analyze the functional impact and therapeutic potential of FAK alterations.
Main Methods:
- Sequenced FAK in 91 lung cancer patients using tumor and normal tissues.
- Analyzed TCGA RNA-seq data for FAK variants.
- Assessed biological functions and inhibitor response of FAK variants in cell lines.
Main Results:
- Identified FAK internal tandem duplication (ITD), A1004S mutation, exon 5-27 deletion, and FAK6,7 splicing variants in 7.7% of patients.
- FAK alterations were more prevalent in smokers.
- FAK-ITD and FAK6,7 variants showed increased autophosphorylation and sensitivity to FAK inhibitors, promoting cell proliferation and migration.
Conclusions:
- Somatic mutations and splicing variants of FAK play a role in lung carcinogenesis.
- FAK alterations represent potential biomarkers for FAK-targeted therapies in lung cancer.
More Related Videos
Related Concept Videos
Cancers Originate from Somatic Mutations in a Single Cell
RNA Splicing
Intracellular Signaling Affects Focal Adhesions
Some...
Abnormal Proliferation
Mitogens and the Cell Cycle

